Sammartino Francesco, Bavishi Sheital, Dalm Brian
Department of Physical Medicine and Rehabilitation, The Ohio State University, Columbus, OH, United States.
Department of Neurological Surgery, The Ohio State University, Columbus, OH, United States.
Front Rehabil Sci. 2025 May 22;6:1530801. doi: 10.3389/fresc.2025.1530801. eCollection 2025.
Intrathecal baclofen (ITB) delivery is an FDA-approved indication for patients with intractable spasticity. Often, implantation in these patients can be considerably challenging, especially if previous surgical fusion involves the procedure access location.
We present the case of a 27-year-old female with T2 American Spinal Injury Association (ASIA) A spinal cord injury (SCI) and chronic spastic dystonia. She was maximized on oral medications without satisfactory control of her painful muscle spasms and was a candidate for ITB trial, which ultimately failed due to the difficulty of accessing the spinal canal due to extensive pseudoarthrosis secondary to thoracic to lumbar fusion. A decision was made to directly implant the pump in the operative room using O-arm-aided neuronavigation to guide catheter access at L5-S1. Currently, at 22 months of follow-up post-pump implant, ITB delivery has led to persistent improvements in her spastic dystonia and many aspects of quality of life.
The current case indicates that a multidisciplinary approach when considering surgical treatments for medication-refractory spasticity may help expand the indications to large numbers of patients with postsurgical spine abnormalities.
鞘内注射巴氯芬(ITB)是美国食品药品监督管理局(FDA)批准用于治疗顽固性痉挛患者的一种方法。通常,在这些患者中进行植入手术可能具有相当大的挑战性,尤其是在先前的手术融合涉及手术入路位置时。
我们报告了一名27岁女性患者的病例,该患者患有美国脊髓损伤协会(ASIA)T2级A类脊髓损伤(SCI)和慢性痉挛性肌张力障碍。她口服药物治疗达到最大剂量,但仍无法满意地控制其疼痛性肌肉痉挛,因此成为ITB试验的候选者,但由于胸腰椎融合术后广泛假关节形成导致难以进入椎管,该试验最终失败。决定在手术室使用O型臂辅助神经导航直接植入泵,以引导在L5-S1水平进行导管置入。目前,在泵植入后22个月的随访中,ITB注射已使其痉挛性肌张力障碍持续改善,并在生活质量的许多方面得到改善。
当前病例表明,在考虑对药物难治性痉挛进行手术治疗时,采用多学科方法可能有助于将适应症扩大到大量有脊柱手术后异常的患者。